VIVEX Biologics, Inc. Launches CYGNUS® Matrix Disks

MIAMI, Aug. 12, 2021 /PRNewswire/ — Vivex Biologics, Inc., a leading regenerative medicine company specializing in the development of naturally sourced treatments, announced today the launch of CYGNUS^® Matrix Disks, the latest configuration from the CYGNUS^® family of amniotic tissue allografts.

CYGNUS^® amniotic tissue allografts are applied as a soft tissue barrier and wound covering to help provide mechanical protection. CYGNUS^® Matrix Disks are a flexible, multi-layer allograft maintaining the amnion layer, its intermediate/spongy layer and the chorion layers of the amniotic sac, providing improved handling and increased workability.

“The innovative technologies associated with CYGNUS^® are transforming the treatment of wound care today,” said Gail Farnan, VP and General Manager of VIVEX’s Wound Care & Amnion Therapies business unit. “Most wounds are not square. Our modern disk design offers a size and shape that reduces the need for cutting to fit the size of the wound, enhancing ease of use and eliminating product waste.”

Amniotic membrane is a semi-transparent and resilient membrane that lines the upper cavity of the placenta. Amniotic tissue acts as an immune-privileged protective barrier during fetal development. CYGNUS^® is applied as a soft tissue barrier and wound covering that helps provide mechanical protection and retains endogenous growth factors.